DRDO issues guidelines with regard to Anti-COVID Drug 2DG

Defence Research and Development Organisation's (DRDO) on Tuesday issued some important guidelines issued with regard to it's anti-Covid-19 drug. 

The 2DG medicine can be given to Covid-19 patients under the care and prescription of doctors. Directions for usage of this drug for Covid-19 patients as per DCGI approval are given below.

The 2-DG drug comes in powder form in the sachet, which is taken orally by dissolving it in water. It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes this drug unique. The drug reportedly reduces a patient's average recovery time by two and a half days and oxygen demand by upto 40 per cent, the Union Health Ministry said.

Important Guidelines With Regard to DRDO Anti-COVID Drug 2DG:

• The 2DG is approved for emergency use as an adjunct therapy to the standard of care in the treatment of COVID patients in hospital settings.
• Ideally, 2DG should be prescribed as early as possible by doctors for moderate to severe COVID patients for a maximum duration of up to 10 days.
• Uncontrolled diabetes severe cardiac problem ARDS severe hepatic and renal impairment patients have not been studied yet with 2DG, and hence caution should be exercised.
• 2DG should not be given to pregnant and lactating women and patients below 18 years.
• Patients and attendants are advised to request the hospital to contact Dr Reddy’s lab Hyderabad for medicine supply at email: 2DG@drreddys.com.
  
  

  The 2DG medicine can be given to Covid-19 patients under the care and prescription of doctors. Directions for usage of this drug for Covid-19 patients as per DCGI approval are attached here for reference. For all queries regarding #2DG, please write to 2DG@drreddys.com pic.twitter.com/x19ayBoToG

  — DRDO (@DRDO_India) June 1, 2021